Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. sold 6,889 shares of the stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $11.57, for a total value of $79,705.73. Following the transaction, the insider now owns 3,124,472 shares of the company's stock, valued at approximately $36,150,141.04. The trade was a 0.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Saba Capital Management, L.P. also recently made the following trade(s):
- On Wednesday, April 2nd, Saba Capital Management, L.P. sold 29,102 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $12.28, for a total value of $357,372.56.
- On Monday, March 31st, Saba Capital Management, L.P. sold 48,623 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $12.58, for a total transaction of $611,677.34.
- On Thursday, March 27th, Saba Capital Management, L.P. sold 32,922 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.01, for a total transaction of $428,315.22.
- On Wednesday, February 26th, Saba Capital Management, L.P. sold 200 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.62, for a total transaction of $2,724.00.
- On Wednesday, February 12th, Saba Capital Management, L.P. sold 36,536 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $13.75, for a total transaction of $502,370.00.
- On Monday, February 10th, Saba Capital Management, L.P. sold 42,987 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $13.95, for a total value of $599,668.65.
- On Monday, February 3rd, Saba Capital Management, L.P. sold 1,846 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.03, for a total value of $25,899.38.
- On Friday, January 31st, Saba Capital Management, L.P. sold 15,143 shares of Abrdn Life Sciences Investors stock. The shares were sold at an average price of $14.27, for a total transaction of $216,090.61.
- On Wednesday, January 29th, Saba Capital Management, L.P. sold 11,674 shares of Abrdn Life Sciences Investors stock. The stock was sold at an average price of $14.12, for a total transaction of $164,836.88.
Abrdn Life Sciences Investors Stock Up 2.6 %
Abrdn Life Sciences Investors stock traded up $0.30 during trading hours on Friday, hitting $11.44. The company had a trading volume of 75,829 shares, compared to its average volume of 101,473. Abrdn Life Sciences Investors has a one year low of $10.55 and a one year high of $15.90. The firm has a 50-day moving average of $13.01 and a 200 day moving average of $13.81.
Abrdn Life Sciences Investors Cuts Dividend
The company also recently declared a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Friday, February 21st were issued a dividend of $0.47 per share. The ex-dividend date was Friday, February 21st. This represents a $1.88 annualized dividend and a yield of 16.44%.
Institutional Trading of Abrdn Life Sciences Investors
Several institutional investors have recently added to or reduced their stakes in the company. 180 Wealth Advisors LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 0.9% during the first quarter. 180 Wealth Advisors LLC now owns 136,122 shares of the company's stock worth $1,727,000 after buying an additional 1,247 shares in the last quarter. Ameriprise Financial Inc. increased its position in Abrdn Life Sciences Investors by 7.5% during the fourth quarter. Ameriprise Financial Inc. now owns 153,396 shares of the company's stock worth $1,999,000 after acquiring an additional 10,742 shares during the period. Jane Street Group LLC acquired a new stake in Abrdn Life Sciences Investors in the 4th quarter worth about $290,000. Stifel Financial Corp boosted its holdings in Abrdn Life Sciences Investors by 67.1% in the 4th quarter. Stifel Financial Corp now owns 28,341 shares of the company's stock valued at $372,000 after purchasing an additional 11,378 shares during the period. Finally, Guggenheim Capital LLC bought a new stake in Abrdn Life Sciences Investors in the 4th quarter valued at about $211,000. 32.21% of the stock is currently owned by institutional investors.
About Abrdn Life Sciences Investors
(
Get Free Report)
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Further Reading
Before you consider Abrdn Life Sciences Investors, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abrdn Life Sciences Investors wasn't on the list.
While Abrdn Life Sciences Investors currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
